LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article: Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.

Bastos-Oreiro, Mariana / Gutierrez, Antonio / Cabero, Almudena / López, Javier / Villafuerte, Paola / Jiménez-Ubieto, Ana / de Oña, Raquel / De la Fuente, Adolfo / Navarro, Belén / Peñalver, Javier / Martínez, Pilar / Alonso, Carmen / Infante, María / Córdoba, Raúl / Perez-Montero, Blanca / Pérez de Oteyza, Jaime / González de Villambrosio, Sonia / Fernández-Caldas, Paula / Del Campo, Raquel /
García Belmonte, Daniel / Diaz-Gálvez, Javier / Salar, Antonio / Sancho, Juan-Manuel

Cancers

2024  Volume 16, Issue 7

Abstract: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for ... ...

Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL. The complete response rate at the end of induction was higher with R-B and relapses were more frequent with R-CHOP. During induction, cytopenias were significantly more frequent with R-CHOP and so was the use of colony-stimulating factors. During maintenance therapy, R-B showed more neutropenia and infectious toxicity. After a median follow-up of 81 months (95% CI: 77-86), the 6-year rates of progression-free survival (PFS) were 79% (95% CI: 72-86) for R-bendamustine vs. 67% (95% CI: 61-73) for R-CHOP (
Language English
Publishing date 2024-03-26
Publishing country Switzerland
Document type Journal Article
ZDB-ID 2527080-1
ISSN 2072-6694
ISSN 2072-6694
DOI 10.3390/cancers16071285
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top